Table 4 Primary and secondary outcomes of AR-Centre and AR-Home participants after 20 training sessions (PP analysis)

FMA-UE^†

40.09±19.69

43.65±19.41

3.57±4.93

37.06±20.91

40.81±20.01

3.75±4.46

− 1.563 (− 3.318

0.906

(Max. 66)

(0.0022**)

(0.0043**)

to 2.948)

FMA-LE^†

19.48±8.18

24.00±6.43

4.52±5.48

17.44±8.50

20.50±9.21

3.06±3.75

2.000 (− 1.741

0.361

(Max. 34)

(0.0007**)

(0.0052**)

to 4.659)

BBS^†

41.35±13.05

43.22±12.59

1.87±5.42

40.25±10.32

43.00±6.02

2.75±6.21

− 1.3125 (− 4.677

0.641

(Max. 56)

(0.0438*)

(0.097)

to 2.916)

FAC^†

4.65±1.19

4.78±1.17

0.13±0.87

4.38±1.15

4.72±1.32

0.34±1.01

− 0.281 (− 0.826

0.485

(Max. 6)

(0.480)

(0.194)

to 0.400)

BI^†

N/A

N/A

N/A

16.31±2.73

17.56±2.53

1.25±1.18

N/A

N/A

(Max. 20)

(0.0007**)

SF-12v2 PCS^†

32.75±14.09

37.58±10.37

4.83±9.79

31.61±9.39

36.42±9.99

4.81±8.35

0.888 (− 6.078

0.996

(Max. 100)

(0.027*)

(0.036*)

to 6.105)

SF-12v2 MCS^†

37.07±19.29

45.07±13.16

8.01± 14.87

45.68±12.68

46.21±9.18

0.53±8.47

8.878 (− 0.877

0.078

(Max. 100)

(0.017*)

(0.807)

to 15.837)